AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|AAPL325.50+8.65 (+2.73%) ▲|ABBV259.91+3.49 (+1.36%) ▲|ABT109.01-1.35 (-1.22%) ▼|ACN187.78-1.98 (-1.04%) ▼|ADBE286.13-6.66 (-2.27%) ▼|AMAT441.46-16.93 (-3.69%) ▼|AMD458.55-12.18 (-2.59%) ▼|AMGN436.55+6.67 (+1.55%) ▲|AMT175.22-0.48 (-0.27%) ▼|AMZN254.36-5.41 (-2.08%) ▼|AVGO369.85-0.49 (-0.13%) ▼|AXP324.87-5.30 (-1.61%) ▼|BA205.97-1.82 (-0.87%) ▼|BAC62.01+0.07 (+0.10%) ▲|BKNG196.38-2.71 (-1.36%) ▼|BLK1,132.28-23.33 (-2.02%) ▼|BMY66.79-0.03 (-0.04%) ▼|BNY160.30-0.98 (-0.61%) ▼|BRK-B502.70-1.34 (-0.26%) ▼|C132.61+0.99 (+0.75%) ▲|CAT778.76-18.71 (-2.35%) ▼|CL89.82-0.01 (-0.01%) ▼|CMCSA26.33-0.30 (-1.11%) ▼|COF211.23-3.28 (-1.53%) ▼|COP135.82+3.33 (+2.51%) ▲|COST936.41-7.48 (-0.79%) ▼|CRM258.02+0.48 (+0.19%) ▲|CSCO109.59-0.90 (-0.81%) ▼|CVS96.70+2.79 (+2.97%) ▲|CVX210.30+4.16 (+2.02%) ▲|DE673.95+19.04 (+2.91%) ▲|DHR207.18-6.38 (-2.99%) ▼|DIS106.39-1.16 (-1.08%) ▼|DUK120.14+0.23 (+0.19%) ▲|EMR147.64-4.80 (-3.15%) ▼|FDX322.27-5.14 (-1.57%) ▼|GD369.56-1.79 (-0.48%) ▼|GE331.05-4.66 (-1.39%) ▼|GEV896.11-2.42 (-0.27%) ▼|GILD149.03+2.69 (+1.83%) ▲|GM85.59-0.74 (-0.85%) ▼|GOOG331.48-3.93 (-1.17%) ▼|GOOGL334.61-4.74 (-1.40%) ▼|GS1,005.29-15.61 (-1.53%) ▼|HD319.07-8.76 (-2.67%) ▼|HON209.85-3.68 (-1.72%) ▼|IBM230.26-3.62 (-1.55%) ▼|INTC88.57-0.94 (-1.05%) ▼|INTU344.30-15.00 (-4.17%) ▼|ISRG367.60-9.27 (-2.46%) ▼|JNJ270.73+4.88 (+1.84%) ▲|JPM355.67-0.35 (-0.10%) ▼|KO88.02-0.65 (-0.73%) ▼|LIN486.14-3.44 (-0.70%) ▼|LLY1,158.16+1.43 (+0.12%) ▲|LMT542.26-15.53 (-2.78%) ▼|LOW199.52-5.18 (-2.53%) ▼|LRCX289.06-12.43 (-4.12%) ▼|MA583.23-6.08 (-1.03%) ▼|MCD261.59-0.09 (-0.03%) ▼|MDLZ61.48-0.59 (-0.95%) ▼|MDT91.91+1.26 (+1.39%) ▲|META579.87+7.53 (+1.32%) ▲|MMM170.62-1.21 (-0.70%) ▼|MO69.91+1.43 (+2.09%) ▲|MRK149.87+2.11 (+1.43%) ▲|MS211.78-1.55 (-0.72%) ▼|MSFT501.02-6.27 (-1.24%) ▼|MU930.78-27.95 (-2.92%) ▼|NEE82.57+0.23 (+0.28%) ▲|NFLX80.85-0.20 (-0.25%) ▼|NKE38.08-0.57 (-1.47%) ▼|NOW143.83-4.16 (-2.81%) ▼|NVDA217.62-2.88 (-1.31%) ▼|ORCL141.13-7.99 (-5.36%) ▼|PEP139.52-0.82 (-0.58%) ▼|PFE28.51+0.05 (+0.18%) ▲|PG146.39+1.27 (+0.88%) ▲|PLTR181.92-4.46 (-2.39%) ▼|PM188.48+1.18 (+0.63%) ▲|QCOM166.67-3.81 (-2.23%) ▼|RTX204.39-3.34 (-1.61%) ▼|SBUX105.66-0.60 (-0.56%) ▼|SCHW108.02-1.80 (-1.64%) ▼|SO88.11+0.11 (+0.12%) ▲|SPG211.67-0.65 (-0.31%) ▼|T26.13+0.24 (+0.93%) ▲|TMO601.80-15.30 (-2.48%) ▼|TMUS182.35+1.91 (+1.06%) ▲|TSLA356.16-11.80 (-3.21%) ▼|TXN253.08-7.83 (-3.00%) ▼|UBER75.22-0.43 (-0.57%) ▼|UNH395.79+6.38 (+1.64%) ▲|UNP288.95-11.72 (-3.90%) ▼|UPS102.51-1.72 (-1.65%) ▼|USB61.02-0.56 (-0.91%) ▼|V373.55-5.83 (-1.54%) ▼|VZ50.43+0.41 (+0.81%) ▲|WFC86.65+0.26 (+0.30%) ▲|WMT105.91+1.04 (+0.99%) ▲|XOM164.33+3.38 (+2.10%) ▲|
26.9 C
New York
Tuesday, September 1, 2026

Tag: therapy

newssourceFORcompanyinformationcontent1releasesmarket

Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced that senior management will participate in the following upcoming investor conferences.  

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today

Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37...

HONG KONG, June 7, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces the presentation of three key studies at the American Diabetes...

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

Zealand Pharma announces Boehringer Ingelheim’s survodutide Phase III trial in people living with obesity showed targeted 34% visceral and 63% liver fat reduction, while...

Company announcement No. 21 / 2026

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 7, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide

NEW ORLEANS, June 8, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences"), a commercial-stage biopharmaceutical company focused on discovering and developing innovative...

Boehringer Ingelheim’s survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and SYNCHRONIZE-MASLD.2,4 The results demonstrate survodutide’s potential to reduce weight and therefore improve metabolic health in two distinct populations: adults living with obesity or overweight, without type 2 diabetes (SYNCHRONIZE-1),2 and adults with overweight or obesity with metabolic dysfunction-associated steatotic liver disease (MASLD) with evidence of inflammation and or fibrosis (SYNCHRONIZE-MASLD).4 Full results from SYNCHRONIZE-1 and SYNCHRONIZE-MASLD were presented today at the American Diabetes Association’s (ADA) 2026 Scientific Sessions and published simultaneously in The New England Journal of Medicine and Nature Medicine respectively.5,6

Once-Weekly Drug Demonstrates Promising Dual Benefits in Obesity and Metabolic Health

Injectable Offers Potential to Reduce Fatty Liver Diseases and Improve Health Markers in AdultsNEW ORLEANS, June 7, 2026 /PRNewswire/ -- New data highlight the potential...

Antag Therapeutics presents positive Phase 1 results at the 2026 Scientific Sessions of the American Diabetes Association for AT7687, a first-in-class GIPR antagonist

Copenhagen, Denmark, 7 June 2026 – Antag Therapeutics (“Antag” or “the Company”), advancing personalized and flexible obesity treatment through GIP receptor antagonism, today presented key Phase 1 and preclinical data for AT7687 at the 2026 Scientific Sessions of the American Diabetes Association®, held in New Orleans, Louisiana from June 5-8, 2026.

Wegovy® pill prescriptions surpass 3 million, 1 filled roughly every 5 seconds, bringing GLP-1 therapy to people with obesity previously untreated, while Novo Nordisk...

Three million prescriptions for Wegovy® pill since launch on January 5th serves as another milestone in one of the strongest US pharmaceutical launches by...

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapy

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers